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ABSTRACT
Objectives Obesity as measured by body mass index
(BMI) is one of the major risk factors for osteoarthritis. In
addition, genetic overlap has been reported between
osteoarthritis and normal adult height variation. We
investigated whether this relationship is due to a shared
genetic aetiology on a genome-wide scale.
Methods We compared genetic association summary
statistics (effect size, p value) for BMI and height from
the GIANT consortium genome-wide association study
(GWAS) with genetic association summary statistics from
the arcOGEN consortium osteoarthritis GWAS.
Signiﬁcance was evaluated by permutation. Replication of
osteoarthritis association of the highlighted signals was
investigated in an independent dataset. Phenotypic
information of height and BMI was accounted for in a
separate analysis using osteoarthritis-free controls.
Results We found signiﬁcant overlap between
osteoarthritis and height (p=3.3×10−5 for signals with
p≤0.05) when the GIANT and arcOGEN GWAS were
compared. For signals with p≤0.001 we found 17 shared
signals between osteoarthritis and height and four
between osteoarthritis and BMI. However, only one of
the height or BMI signals that had shown evidence of
association with osteoarthritis in the arcOGEN GWAS
was also associated with osteoarthritis in the
independent dataset: rs12149832, within the FTO gene
(combined p=2.3×10−5). As expected, this signal was
attenuated when we adjusted for BMI.
Conclusions We found a signiﬁcant excess of shared
signals between both osteoarthritis and height and
osteoarthritis and BMI, suggestive of a common genetic
aetiology. However, only one signal showed association
with osteoarthritis when followed up in a new dataset.
INTRODUCTION
Osteoarthritis is a common complex disease of
synovial joints characterised by degeneration of
hyaline cartilage and bone remodelling, usually
affecting middle-aged to elderly individuals. It is a
leading cause of pain and chronic disability world-
wide.1 Comorbidities such as obesity are frequently
observed with osteoarthritis and epidemiological
studies have noted a link between osteoarthritis
and obesity as measured by body mass index
(BMI). In particular, reports show a consistent rela-
tionship between overweight measures and knee
osteoarthritis.2 Some population studies have
demonstrated that the weight of individuals at
age 37 years (median) could predict the onset of
knee osteoarthritis 36 years later.1 In addition, a
decrease in BMI of two units over the 10 years pre-
ceding diagnosis can reduce the odds of knee osteo-
arthritis.3 A Norwegian population-based study
of approximately 265 000 individuals concluded
that the risk of developing hip osteoarthritis was
dependent on the age at which weight gain was
most dramatic. Younger adults (<20 years) are at
greater risk compared with older individuals
(>30 years).4 In a large prospective population-
based cohort from Iceland the incidence of clinic-
ally severe osteoarthritis (as indicated by arthro-
plasty), in relation to measures of overweight,
found that 36% and 50% of those with hip and
knee osteoarthritis, respectively, had a BMI greater
than 30.5 This is compared with a national preva-
lence of 17% of the adult population (the
International Obesity Task force, http://www.iotf.
org/). Furthermore, the Chingford Study has
demonstrated that in middle-aged women a one
unit increase in BMI is associated with a 10%
increased risk of total knee replacement in the fol-
lowing 19 years.6 There have been a number of
large-scale genome-wide association studies
(GWAS) for obesity and/or BMI, establishing
several genetic loci at genome-wide signiﬁcance
association levels.7–13 Based on the well-established
epidemiological link, we hypothesise here that
osteoarthritis and obesity may have a shared
genetic background.14
Variation in human adult height is also highly
heritable. Numerous studies have identiﬁed over
180 loci to be associated with the trait.15–18 There
is weak or conﬂicting evidence for shared genetic
determinants between osteoarthritis and height.
However, for example, the functional single
nucleotide polymorphism (SNP) (rs143383, T/C)
in the 50 untranslated region of the GDF5 gene,
previously observed to be signiﬁcantly associated
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with osteoarthritis in Asian and European cohorts, is also sig-
niﬁcantly associated with normal variation in human height.19–
23 In addition, height itself has been reported to be a risk factor
for non-generalised severe hip osteoarthritis even after adjusting
for age, gender and BMI.24
The aim of this study was to carry out an investigation of
the genetic overlap between osteoarthritis and the two traits of
BMI and height by examining the overlap of SNPs association
signals across the genome. This may uncover possible common
mechanistic pathways.
MATERIALS AND METHODS
Description of datasets
Genome-wide summary statistics (effect size, p values) for BMI
and height from the Genetic Investigation of Anthropometric
Traits (GIANT) consortium GWAS were compared with
genome-wide osteoarthritis data from the arcOGEN consor-
tium. The GIANT consortium has brought together GWAS
data from 46 studies.25 26 Overlap analysis with osteoarthritis
utilised 2 400 344 SNPs and 32 387 individuals from the BMI
dataset and 2 834 208 SNPs and 133 653 individuals from the
height dataset.
The arcOGEN GWAS was carried out in two stages and
includes a total of 7567 osteoarthritis cases from the UK (ascer-
tained by radiographic evidence of disease, Kellgren–Lawrence
score ≥2, or clinical evidence of the disease to a level requiring
total joint replacement) genotyped on the Illumina HumanHap
610-Quad panel. Stage 1 of the arcOGEN GWAS was employed
in the main overlap analysis and included 3177 osteoarthritis
cases and 4894 population-based controls from the UK
(WTCCC2).27 Genotypes of 17 SNPs that were imputed in
arcOGEN stage 1 were validated by direct typing using
Sequenom in the stage 1 cases (n=2949) and examining con-
cordance. Replication of association with osteoarthritis for the
signals highlighted from the overlap analysis (tables 1 and 2)
was carried out using 4324 stage 2 cases from the arcOGEN
Consortium and 6518 population-based controls (from the
WTCCC2, T1DGC, ALSPAC study and PoBI studies) (see
supplementary methods, available online only). SNPs that were
not genotyped in the stage 2 arcOGEN GWAS or did not pass
quality control were genotyped with Sequenom in 5165 cases
and 6115 controls (see supplementary methods, available
online only).
Analysis accounting for phenotypic information of height
and BMI was carried out using 1671 unrelated female indivi-
duals from the osteoarthritis-free TwinsUK cohort as a control
set. This cohort is ascertained to study the heritability of
age-related diseases and contains full phenotypic information
for osteoarthritis status as well as height and BMI.24 Additional
quality control that was performed for this study is described
in the supplementary methods (available online only).
arcOGEN stage 1 female cases (n=1009 for height; n=1358 for
BMI) were utilised for these analyses.
Osteoarthritis replication genotyping
Osteoarthritis association signals at directly typed variants,
highlighted in tables 3 and 4, were followed up through
in-silico replication using stage 2 arcOGEN GWAS data (see
supplementary methods, available online only). Association
signals at imputed variants were followed up by carrying out
de-novo genotyping in 5165 arcOGEN stage 2 cases and 6115
WTCCC2 controls using the Sequenom MassArray iPLex Gold
assay at the Wellcome Trust Sanger Institute. Genotypes were
assigned using the MassArray TyperAnalyser software V.4.0
(Sequenom). All genotypes were conﬁrmed manually and
passed standard quality control checks (see supplementary
methods, available online only).
Analysis strategy
We carried out pairwise comparisons between osteoarthritis
and height and between osteoarthritis and BMI genome-wide
summary statistics. For each comparison, we focused on the
intersection of SNPs for which summary statistics were present
in both GWAS. We then sorted these SNPs based on association
p value for osteoarthritis. This list of SNPs was then thinned
to an independent unlinked set using an r2 threshold of 0.05
based on HapMap CEU release #27. Starting with the ﬁrst
SNP in the list, any subsequent SNP with r2>0.05 was
removed and then the next available SNP was taken. This
Table 1 Shared genetic determinants (p≤1.0×10−3) between osteoarthritis and height
SNP Chromosome Allele Osteoarthritis p value Osteoarthritis OR 95% CI Height p value Height OR 95% CI Nearest gene
rs2744718 1 T 8.9×10−5 1.20 1.10 to 1.31 3.5×10−5 0.98 0.97 to 0.99 WNT4
rs6670486 1 T 9.6×10−5 1.16 1.07 to 1.24 6.5×10−7 0.98 0.98 to 0.98 COL11A1
rs4833772 4 G 2.5×10−4 1.12 1.05 to 1.19 1.3×10−5 1.02 1.01 to 1.02 TMEM155
rs572004 6 G 2.4×10−4 1.14 1.06 to 1.22 7.5×10−5 0.98 0.97 to 0.99 EYA4
rs3822856 6 A 9.2×10−4 1.12 1.05 to 1.19 6.5×10−4 0.99 0.98 to 0.99 NT5DC1
rs1635853 7 T 2.0×10−5 1.15 1.08 to 1.22 8.8×10−21 1.04 1.03 to 1.04 JAZF1
rs10094727 8 A 3.7×10−4 1.23 1.10 to 1.39 6.0×10−5 0.97 0.06 to 0.98 MSR1
rs9657371 8 A 1.3×10−4 1.13 1.06 to 1.21 2.7×10−5 0.98 0.97 to 0.99 CSMD1
rs11991139 8 C 6.2×10−5 1.14 1.06 to 1.22 4.3×10−4 0.98 0.98 to 0.99 BLK
rs3808880 9 G 7.5×10−4 1.13 1.05 to 1.21 6.8×10−4 1.01 1.01 to 1.02 ROD1
rs11198893 10 A 3.8×10−4 1.22 1.09 to 1.36 5.7×10−4 1.02 1.01 to 1.03 GRK5
rs7932272 11 A 1.1×10−4 1.30 1.12 to 1.52 2.4×10−7 1.04 1.03 to 1.06 PACS1
rs7297051 12 T 3.3×10−4 1.14 1.05 to 1.23 6.0×10−5 1.02 1.01 to 1.03 PTHLH
rs10506474 12 C 5.2×10−4 1.15 1.06 to 1.27 4.4×10−5 0.99 0.97 to 0.99 HMGA2
rs4793927 17 C 1.4×10−4 1.14 1.06 to 1.22 3.0×10−6 1.02 1.01 to 1.03 HOXB3
rs2864419 19 G 8.4×10−5 1.14 1.07 to 1.21 1.1×10−12 1.03 1.02 to 1.04 DOT1L
rs8105885 19 T 7.9×10−4 1.20 1.08 to 1.37 4.3×10−4 0.98 0.96 to 0.98 ZNF98
SNP, single nucleotide polymorphism.
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continued until a set of independent SNPs was obtained (osteo-
arthritis–BMI n=62 280, osteoarthritis–height n=64 702).
We investigated the distribution of p values above and below
given thresholds (0.5, 0.1, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005,
0.001, 0.0005) for each trait. The distribution of counts in the
resulting 2×2 contingency tables was analysed using the χ2
test. A signiﬁcant excess of signals with p values less than the
given threshold for both phenotypes was taken to indicate a
concurrence of signals.
In addition, we examined the SNPs for each comparative ana-
lysis of osteoarthritis–height and osteoarthritis–BMI to see if
there was an overabundance of discordant or concordant risk
alleles between the datasets (see supplementary methods, avail-
able online only).
Permutations
Based on the results obtained for the analysis of the signal
overlap between the osteoarthritis–height and osteoarthritis–
BMI comparisons (table 5), we selected p value thresholds of
0.001 (osteoarthritis–BMI) and 0.05 (osteoarthritis–height)
for further follow-up. We permuted the p value signals for
the entire datasets as well as for linkage disequilibrium
(LD)-thinned data of r2= 0.2 and 0.05. We generated 100 000
permutations of the arcOGEN case–control data using PLINK28
(make-perm-pheno command) and performed a GWAS for each
permutation under the log-additive model. We carried out the
overlap analysis for each permuted case–control dataset consid-
ering only SNPs that were directly typed in arcOGEN and
present in the GIANT data. We thus generated a null distribu-
tion of p values. From this we calculated the probability of
seeing an overlap p value equal to or less than the original p
value for directly typed SNPs.
In addition, we sought to get a more precise empirical p
value for the osteoarthritis–height comparison as this gave the
most compelling results for the signal overlap analysis (table 5).
Using the LD-thinned data (r2= 0.05) and p value threshold of
0.05, we generated 500 000 000 permutations of the arcOGEN
and GIANT height datasets by permuting which p value was
associated with which SNP. We performed 500 000 000 overlap
analyses by randomly choosing without replacement a permu-
tation from each dataset to generate the null distribution of
overlap p values, given a speciﬁc distribution of original p
values. From this constructed null distribution of p values we
calculated the probability of seeing an overlap p value equal to
or less than the original overlap p value for the entire dataset.
Replication of osteoarthritis association for overlapping
signals
Case–control association analysis under the log-additive model
was carried out using PLINK for directly typed SNPs and
SNPTEST for imputed SNPs.28 30 Combined estimates of OR
and p values for stages 1 and 2 of arcOGEN were obtained
Table 3 Replication of osteoarthritis association at shared genetic determinants between osteoarthritis and height
Stage 1 Stage 2 Combined
SNP Chromosome p Value OR 95% CI P Value OR 95% CI p Value OR 95% CI
rs2744718†‡ 1 8.9×10−5 1.20 1.10 to 1.31 Failed QC Failed QC
rs6670486 1 9.6×10−5 1.16 1.07 to 1.24 0.58 1.02 0.96 to 1.08 3.5×10−3 1.07 1.02 to 1.12
rs4833772* 4 2.5×10−4 1.12 1.05 to 1.19 0.24 0.97 0.92 to 1.02 1.6×10−1 1.03 0.99 to 1.07
rs572004 6 2.4×10−4 1.14 1.06 to 1.22 0.29 1.03 0.97 to 1.09 9.0×10−4 1.07 1.03 to 1.14
rs3822856 6 9.2×10−4 1.12 1.05 to 1.19 0.29 1.02 0.97 to 1.09 2.5×10−3 1.06 1.02 to 1.11
rs1635853 7 2.0×10−5 1.15 1.08 to 1.22 0.56 1.02 0.96 to 1.07 4.4×10−4 1.08 1.03 to 1.12
rs10094727‡ 8 3.7×10−4 1.23 1.10 to 1.39 0.80 0.99 0.89 to 1.09 3.0×10−2 1.09 1.01 to 1.17
rs9657371‡ 8 1.3×10−4 1.13 1.06 to 1.21 0.60 1.02 0.96 to 1.07 3.7×10−3 1.06 1.02 to 1.11
rs11991139* 8 6.2×10−5 1.14 1.06 to 1.22 0.37 1.02 1.0 to 1.09 3.1×10−3 1.05 1.02 to 1.10
rs3808880* 9 7.5×10−4 1.13 1.05 to 1.21 0.03 0.94 0.88 to 0.99 5.6×10−1 1.01 0.97 to 1.06
rs11198893†‡ 10 3.8×10−4 1.22 1.09 to 1.36 Failed QC
rs7932272 11 1.1×10−4 1.30 1.12 to 1.52 0.08 1.10 0.99 to 1.20 5.2×10−4 1.16 1.06 to 1.26
rs7297051 12 3.3×10−4 1.14 1.05 to 1.23 0.15 0.95 0.89 to 1.01 4.1×10−1 1.02 0.97 to 1.07
rs10506474 12 5.2×10−4 1.15 1.06 to 1.27 0.37 0.97 0.90 to 1.04 1.5×10−1 1.04 0.98 to 1.09
rs4793927 17 1.4×10−4 1.14 1.06 to 1.22 0.29 0.97 0.92 to 1.03 1.2×10−1 1.03 0.99 to 1.07
rs2864419‡ 19 8.4×10−5 1.14 1.07 to 1.21 0.72 1.01 0.96 to 1.07 4.6×10−3 1.06 1.02 to 1.11
rs8105885 19 7.9×10−4 1.20 1.08 to 1.37 0.15 0.93 0.85 to 1.03 3.2×10−1 1.04 0.96 to 1.12
*Proxies used for analysis due to failure of SNP in stage 2 replication. Proxy for rs4833772 is rs4833233 (r2= 1), for rs11991139 is rs13280813 (r2= 0.94) and for rs3808880 is
rs13293285 (r2= 0.89).
†No proxies found for r2> 0.3 (rs2744718); r2> 0.43 (rs11198893).
‡Directly typed SNP analysed from arcOGEN genome-wide association scan.
QC, qualtiy control; SNP, single nucleotide polymorphism.
Table 2 Shared genetic determinants (p≤1.0 × 10−3) between osteoarthritis and BMI
SNP Chromosome Allele Osteoarthritis p value Osteoarthritis OR 95% CI BMI p value BMI z score Nearest gene
rs4856346 3 T 6.1×10−4 1.14 1.05 to 1.22 7.1×10−4 3.48 GBE1
rs7828042 8 G 1.1×10−4 1.14 1.07 to 1.22 2.1×10−4 4.05 SLURP1
rs7203219 16 T 3.5×10−4 1.19 1.08 to 1.31 3.4×10−4 3.87 GPR139
rs12149832 16 A 2.8×10−4 1.12 1.06 to 1.20 1.9×10−16 8.47 FTO
BMI, body mass index; SNP, single nucleotide polymorphism.
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using ﬁxed-effect meta-analyses in GWAMA.29 Heterogeneity
was checked using the Cochran’s Q and I2 statistics.
Analysis with adjustment for BMI and height
In order to adjust for height and BMI as covariates, we repeated
the case–control analysis for stage 1 of the arcOGEN dataset
using the TwinsUK cohort as controls. Analysis was carried out
using PLINK when the SNPs were directly typed or SNPTEST30
when they were imputed. The analysis was performed twice;
with and without an adjustment for height and BMI.
RESULTS
Overlapping signals and permutations
Our ﬁndings suggest an excess of shared signals both between
osteoarthritis and height and osteoarthritis and BMI. A com-
parison of signals indicates an excess of sharing at p value
thresholds of 0.05, 0.04, 0.03, 0.02 and 0.01 for osteoarthritis
and height; there is evidence for overlap between osteoarthritis
and BMI at the p value thresholds of 0.005, 0.001 and 0.0005
(table 5).
To test the strength of the observed overlap we ran a series
of permutations (table 6). The LD-thinned datasets provide the
most robust results because the probability of seeing an overlap
p value equal to or less than the original analysis p value by
chance is unlikely. Both comparisons of osteoarthritis–height
and osteoarthritis–BMI showed an excess of overlapping signals
(p=1.4×10−3 for the 0.05 p value threshold and p=2.28×10−2
for the 0.001 p value threshold). Based on these results we per-
formed 500 000 000 permutations of the entire LD-thinned
(r2= 0.05) height dataset. This showed that the probability of
seeing a p value less than or equal to 3.04×10−5 was 3.3×10−5.
A total of 17 SNPs with p values of 1.0×10−3 or less were
shared between osteoarthritis and height (table 1), while four
SNPs were shared between osteoarthritis and BMI (table 2).
These SNPs were distributed throughout the genome (11 chro-
mosomes in the osteoarthritis–height comparison and three
chromosomes in the osteoarthritis–BMI comparison). Some
of these signals, such as the ones near COL11A1, PTHLH and
FTO are well-known loci with established associations with
bone development, bone mineral density and obesity,
respectively.8 19 31
Replication of osteoarthritis association
To evaluate the observed overlap further we attempted to repli-
cate osteoarthritis association of these 21 signals employing
stage 2 of the arcOGEN dataset (tables 3 and 4). Seven of the
SNP failed quality control in stage 2 and proxies (r2>0.85) were
sought. No proxies were found for two of the seven SNPs,
rs2744718 and rs11198893. Of the 19 SNPs successfully taken
forward for validation, rs12149832 on chromosome 16 within
the FTO gene was the only one found to be associated
(p<0.01) with osteoarthritis in the replication dataset
(p=0.009, in the same direction). The combined p value of
both stages increased in signiﬁcance for this SNP relative to
stage 1 alone (p=2.8×10−4 for stage 1 vs p=2.3×10−5 for
stages 1 and 2 combined, table 4).
Adjustment for BMI and height
Adjustment for height and BMI (tables 7 and 8) only affected
the signal at the FTO SNP rs12149832. Here we found an eight-
fold increase in the p value after adjustment for BMI
(p=0.22576) compared with the unadjusted result
(p=0.029219).
DISCUSSION
Identiﬁcation of the genetic loci contributing to variation in
quantitative traits such as height and BMI, and risk of osteo-
arthritis could help elucidate possible mechanistic pathways.
There is an established genetic link between height and osteo-
arthritis. The pleiotropic action of GDF5 on human height is
an example that may shed light on shared signalling functions
and pathways affecting the two traits.19 Epidemiological evi-
dence has also suggested a link between osteoarthritis and
BMI.32 It is plausible that these traits also share genetic associa-
tions and we carried out a SNP-by-SNP pairwise comparison of
GWAS data to investigate their genetic overlap.
We obtained evidence for overlap of association signals between
osteoarthritis and height and between osteoarthritis and BMI at
different deﬁnition thresholds, corroborated by permutation ana-
lyses to obtain empirical p values. We investigated speciﬁc signals
Table 4 Replication of osteoarthritis association at shared genetic determinants between osteoarthritis and body mass index
Stage 1 Stage 2 Combined
SNP Chromosome p Value OR 95% CI p Value OR 95% CI p Value OR 95% CI
rs4856346* 3 6.1×10−4 1.14 1.06 to 1.23 0.87 0.99 0.94 to 1.06 0.041 1.05 1.00 to 1.10
rs7828042† 8 1.1×10−4 1.14 1.07 to 1.22 0.45 0.98 0.92 to 1.04 0.050 1.04 1.00 to 1.08
rs7203219† 16 3.5×10−4 1.19 1.08 to 1.31 0.92 1.01 0.93 to 1.09 0.016 1.08 1.01 to 1.15
rs12149832* 16 2.8×10−4 1.12 1.06 to 1.20 0.009 1.07 1.02 to 1.14 2.3 × 10−5 1.10 1.05 to 1.15
*Proxies (r2> 0.93) were used for analysis due to failure of SNP in stage 2 replication. Proxy for rs4856346 is rs898763 (r2= 1), for rs12149832 is rs8050136 (r2= 0.93).
†Directly typed SNP from arcOGEN genome-wide association scan.
SNP, single nucleotide polymorphism.
Table 5 Analysis of shared excess signals between osteoarthritis and
normal height variation and osteoarthritis and BMI
Osteoarthritis–normal adult
height comparison
Osteoarthritis–BMI
comparison
Total no of
SNPs 62280 64702
Signal
definition
(p value)
Overlapping
SNPs (n)
p Value for
overlap
Overlapping
SNPs (n)
p Value for
overlap
0.5 28194 0.5189 23526 0.4299
0.1 3571 0.0026 1867 0.5814
0.05 1491 3.04×10−5 584 0.7483
0.04 1160 1.00×10−6 412 0.6315
0.03 814 1.00×10−6 267 0.1715
0.02 511 1.00×10−16 143 0.0368
0.01 213 6.20×10−4 50 0.0356
0.005 92 0.0173 20 0.0057
0.001 17 0.5999 4 1.2×10−5
0.0005 8 0.1278 3 4.8×10−17
BMI, body mass index; SNP, single nucleotide polymorphism.
938 Ann Rheum Dis 2013;72:935–941. doi:10.1136/annrheumdis-2012-202081
Clinical and epidemiological research
that may be representative of these ﬁndings and looked at all
SNPs with p≤1.0×10−3 for both comparisons. Some signals
reside in the vicinity of genes, such as the structural protein colla-
gen gene COL11A1 and the parathyroid hormone-related protein
PTHLH that regulates endochondral bone development, which
have previously been identiﬁed as possible candidates for osteo-
arthritis susceptibility.33–36 For the osteoarthritis–BMI compari-
son the FTO gene for obesity was highlighted.
Using a second dataset we attempted to replicate the osteo-
arthritis association of overlapping signals. The fact that the
FTO locus was the only one to replicate in our second osteoarth-
ritis dataset suggests that the other signals may have been false
positive signals for osteoarthritis, or low power in the replication
cohort. Adjustment for BMI attenuated this osteoarthritis
signal, indicating that the primary association is with BMI.
The established osteoarthritis and height overlapping signal
rs143383 located in GDF5 was not identiﬁed in this analysis.
We found it to be strongly associated with height
(p=1.94×10−50), but not associated with osteoarthritis in the
arcOGEN dataset (p=0.602). Although association between
the GDF5 locus and hip and knee osteoarthritis was ﬁrst
reported in a study of Japanese and Chinese individuals in
2007,20 it took several years and large-scale meta-analysis
efforts to replicate the association robustly in European popula-
tions.21–23 In addition to allele frequency disparities between
ethnic groups, this observation also highlights the limited
power (<10% at α=5×10−8) of a dataset such as arcOGEN
(comprising 3177 cases and 4894 controls) to detect a signal
with modest effect (OR 1.15) and common risk allele fre-
quency (∼0.60 for the GDF5 signal).27 Our results should be
interpreted within the power constraints of our study. First,
osteoarthritis is a heterogeneous disease and the deﬁnition of
the cases here was primarily based on painful rather than struc-
tural osteoarthritis. Second, we examined GWAS platform SNP
content rather than known causal variants. Finally, the osteo-
arthritis GWAS used population-based controls, which can
dilute power due to misclassiﬁcations of cases as controls in a
common disease such as osteoarthritis.
In conclusion, our genome-wide comparison of GIANT and
arcOGEN generated evidence for an overall excess of overlap-
ping signals between osteoarthritis and the two quantitative
traits of BMI and height. The FTO signal was robustly asso-
ciated with BMI and osteoarthritis, and showed evidence of
association in the replication osteoarthritis dataset. This signal
underpins the known epidemiological link between BMI and
osteoarthritis, and represents the single largest genetic effect
for BMI, which may have facilitated its identiﬁcation as a
shared locus. Better-powered GWAS datasets, along with
large-scale replication samples, will help unveil additional
shared loci and highlight common biological pathways.
Table 7 Results of osteoarthritis association analysis adjusting for height
Unadjusted Adjusted
SNP Chromosome Allele OR 95% CI p Value OR 95% CI p Value
rs2744718 1 T 0.94 0.80 to 1.10 0.437 0.94 0.80 to 1.10 0.442
rs6670486 1 T 1.19 1.05 to 1.36 0.007 1.19 1.05 to 1.36 0.006
rs4833772 4 G 1.01 0.90 to 1.13 0.877 1.01 0.90 to 1.13 0.945
rs572004 6 G 1.08 0.96 to 1.22 0.201 1.08 0.96 to 1.22 0.210
rs3822856 6 A 1.02 0.91 to 1.14 0.694 1.02 0.91 to 1.14 0.678
rs1635853 7 T 1.17 1.04 to 1.31 0.008 1.17 1.04 to 1.31 0.007
rs10094727 8 A 0.87 0.71 to 1.10 0.161 0.87 0.71 to 1.06 0.186
rs9657371 8 A 0.92 0.82 to 1.03 0.168 0.93 0.83 to 1.04 0.158
rs11991139 8 C 1.03 0.92 to 1.15 0.601 1.03 0.92 to 1.15 0.491
rs3808880 9 G 0.99 0.88 to 1.12 0.946 0.99 0.88 to 1.12 0.980
rs11198893 10 A 1.22 1.02 to 1.45 0.025 1.25 1.05 to 1.49 0.013
rs7932272 11 A 1.12 0.85 to 1.37 0.195 1.12 0.85 to 1.37 0.174
rs7297051 12 T Failed QC
rs10506474 12 C 1.22 1.06 to 1.398 0.006 1.22 1.06 to 1.40 0.009
rs4793927 17 C 1.13 1.01 to 1.26 0.037 1.13 1.01 to 1.26 0.028
rs2864419 19 G Failed QC
rs8105885 19 T 1.16 0.95 to 1.42 0.149 1.16 0.95 to 1.42 0.154
QC, qualtiy control; SNP, single nucleotide polymorphism.
Table 6 Permutation results for osteoarthritis–height (p value threshold 0.05) and osteoarthritis–BMI overlap (p value threshold 0.001)
Osteoarthritis–adult height comparison Osteoarthritis–BMI comparison
All data r2= 0.2 r2= 0.05 All data r2= 0.2 r2= 0.05
No of SNPs† 489098 63802 27728 461707 55275 24599
p Value* 0 2.62×10−7 3.04×10−5 0 6.41×10−5 1.24×10−5
Tested p value** 3.30×10−6 5.33×10−6 1.10×10−3 6.19×10−11 2.91×10−4 2.25×10−4
No of permutations 100000 100000 100000 100000 100000 100000
Permutation p value 0.0128 <1×10−5 0.0014 0.00374 0.04716 0.02288
†Directly typed only analysed.
*p Value of original analysis.
**p Value of the overlap for directly typed SNPs only. This is the p value that the permutation analysis is tested against.
BMI, body mass index; SNPs, single nucleotide polymorphism.
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